Key Highlights

  • ConvaTec, the Reading-based FTSE 100 medical-technology group, has quietly transformed itself over the past few years from a sleepy chronic-care supplier into a more disciplined, faster-growing MedTech business.
  • Its products address unglamorous but essential needs — advanced wound care, ostomy care, continence care and infusion devices — markets defined by ageing populations, chronic disease and recurring.
  • Revenue for the six months to 30 June 2026 rose 4.4% to $1,232m, with organic growth of 5.0% once the InnovaMatrix impact is stripped out.
  • Adjusted operating profit increased 3.9% to $262m and adjusted diluted EPS climbed 6.3%.

ConvaTec, the Reading-based FTSE 100 medical-technology group, has quietly transformed itself over the past few years from a sleepy chronic-care supplier into a more disciplined, faster-growing medtech business. Its products address unglamorous but essential needs — advanced wound care, ostomy care, continence care and infusion devices — markets defined by ageing populations, chronic disease and recurring, consumable-driven demand. After a multi-year turnaround under its 'Accelerate' strategy, the first-half 2026 results raise a genuine question: is the market still underestimating the durability of ConvaTec's improved growth? The consumable model gives the Business a defensive, annuity-like quality that the market has historically rated cautiously.

Broad-based first-half growth

Revenue for the six months to 30 June 2026 rose 4.4% to $1,232m, with organic growth of 5.0% once the InnovaMatrix impact is stripped out. Adjusted operating profit increased 3.9% to $262m and adjusted diluted EPS climbed 6.3%. Management described the growth as broad-based across all chronic-care categories, singling out strong Demand in infusion care linked to diabetes and Parkinson's therapies, alongside successful launches such as ConvaFoam, Esteem Body and GentleCath Air. The Interim Dividend was raised 15% and a $200m share buyback was launched, signalling confidence in cash generation. The step-up in the dividend and the buyback together mark a shift toward returning more Capital as the turnaround matures. The organic figure, stripping out the InnovaMatrix distortion, is the cleaner read on underlying momentum and points to steady rather than spectacular expansion.

The business model and its appeal

ConvaTec's attraction lies in the recurring, consumable nature of its revenue: patients using ostomy, continence or wound-care products typically need them continuously, generating steady, defensive cash flows relatively insulated from economic cycles. The four franchises give diversification, while infusion care — supplying devices for drug delivery in diabetes and neurological conditions — offers a higher-growth angle tied to the expansion of injectable therapies. The strategic emphasis has been on innovation, commercial execution and Margin discipline, moving the group up the value chain from a commoditised supplier toward a genuine medtech innovator. Demographic tailwinds are powerful: ageing populations and rising rates of diabetes and obesity steadily enlarge the pool of patients its products serve. Switching costs are meaningful too, since patients and clinicians tend to stay loyal to products that work reliably, giving ConvaTec sticky, repeat demand.

Margins, guidance and a US setback

The half was not without blemish: a non-cash Impairment of around $69m was booked against InnovaMatrix following US reimbursement changes, a reminder that healthcare pricing and coverage decisions can move quickly. Nonetheless, management reaffirmed full-year guidance of mid-single-digit organic Revenue growth, operating-margin expansion to at least 23%, double-digit EPS growth and roughly 100% Equity cash conversion. Medium-term 'Accelerate' targets envisage sustainable 6-8% annual revenue growth from 2027 and operating margins in the mid-20s — a step-change if delivered, and the crux of the case that consensus may be too cautious. The impairment also underlines how dependent parts of the portfolio are on the decisions of US payers and government reimbursement bodies. Margin expansion, if delivered alongside revenue growth, is the mechanism by which management expects Earnings to compound faster than the top line.

Outlook

Risks include US reimbursement and pricing pressure, competition across all four franchises, currency translation for a dollar-reporting group, supply-chain and Manufacturing execution, and the possibility that infusion-care momentum tied to specific therapies proves lumpy. Potential catalysts investors may watch include second-half margin acceleration, continued new-product traction, delivery against the 2027 growth targets, and progress on the buyback. The key question is whether ConvaTec can sustain mid-single-digit-plus organic growth with expanding margins — and whether a market that has long treated it as a defensive laggard begins to re-rate it as a compounding medtech grower. Sustained delivery against guidance, rather than any single product launch, is likely to be what shifts that perception. A dollar-reporting base also means sterling investors carry currency risk, and a stronger pound would translate reported results lower even if the underlying business performs.